컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

The European Society for Medical Oncology Gynaecological Cancers Annual Congress 2025 (ESMO Gyn 2025)

19 June - 21 June, 2025, Austria

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

2025-09-17

Data presented at ESMO Gyn 2025 support apixaban as a prophylactic agent for venous thromboembolism (VTE) in women with epithelial ovarian cancer who are undergoing neoadjuvant chemotherapy consisting of carboplatin and paclitaxel.
Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

2025-09-17

The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1? persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.
Raludotatug deruxtecan shows efficacy signal in platinum-sensitive ovarian cancer

2025-09-17

The cadherin 6 (CDH6)-directed antibody?drug conjugate raludotatug deruxtecan elicits response in heavily pretreated patients with platinum-sensitive ovarian cancer while having a manageable safety profile, according to a subgroup analysis of an ongoing first-in-human phase I trial.
Real-world data support HPV vaccine efficacy in off-label age groups

2025-09-17

A prospective analysis demonstrates the effectiveness of HPV vaccination in reducing progression to biopsy-confirmed precancerous lesions and HPV persistence in a cohort of South Korean women in off-label age groups.
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

2025-09-17

The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.
Selinexor maintenance shows consistent benefit in TP53wt endometrial cancer

2025-09-17

Selinexor maintenance therapy continues to show consistent clinical benefit in patients with TP53 wild-type (TP53wt) advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status, according to the ENGOT-EN5/GOG-3055/SIENDO trial presented at ESMO Gyn 2025.
Thumbs up for rucaparib maintenance across prognostic subgroups of HRD-negative ovarian cancer

2025-09-17

Maintenance with the PARP inhibitor rucaparib after first-line platinum-doublet chemotherapy and cytoreductive surgery appears to reduce the risk of progression in the homologous recombination deficiency (HRD)-negative population of patients with advanced, high-grade ovarian cancer enrolled in the phase III ATHENA-MONO trial, no matter the prognostic factor.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브